Jing et al. found that in intrahepatic cholangiocarcinoma (ICC), HHLA2 expression is weak in peritumoral tissues, while 49.0% and 67.7% of patients in the training and validation cohorts, respectively, exhibited strong HHLA2 expression [13]. The gene discussed is HHLA2; the disease is intrahepatic cholangiocarcinoma.